H A Torres1, D P Kontoyiannis, K V I Rolston. 1. Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 402, Houston, TX 77030, USA.
Abstract
BACKGROUND: Response rates for candidemia treated with standard-dose fluconazole (400 mg/day) are approximately 70%. Higher doses of fluconazole have been recommended for susceptible dose-dependent Candida isolates. Herein, we describe the outcome of 20 patients with solid tumors and candidemia treated with high-dose fluconazole (HDF) at The University of Texas M.D. Anderson Cancer Center (1998-2002). PATIENTS AND METHODS: Patients were identified either by searching the microbiology laboratory database or through direct referral from primary oncology services to the Infectious Diseases Consultative Services. A retrospective review of cases was performed. HDF was defined as > or =600 mg/day. RESULTS: Five patients were treated with 600 mg/day, whereas 15 patients received 800 mg/day. Only one patient was neutropenic. The median APACHE II score at the onset of candidemia was 12 (range 6-24). The most common species identified were Candida albicans (eight patients, 40%) and Candida parapsilosis (seven patients, 35%). Of 19 patients whose quantitative data were available, eight (42%) had high-grade candidemia [> or =200 colony forming units (CFU)/ml]. Fifteen (83%) of 18 isolates were fluconazole susceptible, and two (both Candida glabrata) were fluconazole resistant (MIC 64 each) in vitro. Nineteen patients (95%) responded to HDF therapy. The only HDF failure occurred in a patient with C. glabrata (MIC 64.0) infection. The other patient with C. glabrata (MIC 64.0) infection responded to HDF. Central venous catheters were removed from all patients with > or =10 CFU/ml candidemias. All patients with high-grade candidemias responded to HDF. The median duration of HDF therapy was 16 (range 6-42) days. No significant toxicity occurred. CONCLUSIONS: Although our data are limited, HDF appears to be well tolerated and may be associated with higher response rates than standard-dose fluconazole in a selected group of patients with solid tumors and candidemia caused by species that are susceptible to this triazole.
BACKGROUND: Response rates for candidemia treated with standard-dose fluconazole (400 mg/day) are approximately 70%. Higher doses of fluconazole have been recommended for susceptible dose-dependent Candida isolates. Herein, we describe the outcome of 20 patients with solid tumors and candidemia treated with high-dose fluconazole (HDF) at The University of Texas M.D. Anderson Cancer Center (1998-2002). PATIENTS AND METHODS: Patients were identified either by searching the microbiology laboratory database or through direct referral from primary oncology services to the Infectious Diseases Consultative Services. A retrospective review of cases was performed. HDF was defined as > or =600 mg/day. RESULTS: Five patients were treated with 600 mg/day, whereas 15 patients received 800 mg/day. Only one patient was neutropenic. The median APACHE II score at the onset of candidemia was 12 (range 6-24). The most common species identified were Candida albicans (eight patients, 40%) and Candida parapsilosis (seven patients, 35%). Of 19 patients whose quantitative data were available, eight (42%) had high-grade candidemia [> or =200 colony forming units (CFU)/ml]. Fifteen (83%) of 18 isolates were fluconazole susceptible, and two (both Candida glabrata) were fluconazole resistant (MIC 64 each) in vitro. Nineteen patients (95%) responded to HDF therapy. The only HDF failure occurred in a patient with C. glabrata (MIC 64.0) infection. The other patient with C. glabrata (MIC 64.0) infection responded to HDF. Central venous catheters were removed from all patients with > or =10 CFU/ml candidemias. All patients with high-grade candidemias responded to HDF. The median duration of HDF therapy was 16 (range 6-42) days. No significant toxicity occurred. CONCLUSIONS: Although our data are limited, HDF appears to be well tolerated and may be associated with higher response rates than standard-dose fluconazole in a selected group of patients with solid tumors and candidemia caused by species that are susceptible to this triazole.
Authors: L A Mermel; B M Farr; R J Sherertz; I I Raad; N O'Grady; J S Harris; D E Craven Journal: Clin Infect Dis Date: 2001-04-03 Impact factor: 9.079
Authors: Gerald P Bodey; Masoud Mardani; Hend A Hanna; Maha Boktour; Jalal Abbas; Essam Girgawy; Ray Y Hachem; Dimitrios P Kontoyiannis; Issam I Raad Journal: Am J Med Date: 2002-04-01 Impact factor: 4.965
Authors: John H Rex; Peter G Pappas; Adolf W Karchmer; Jack Sobel; John E Edwards; Susan Hadley; Corstiaan Brass; Jose A Vazquez; Stanley W Chapman; Harold W Horowitz; Marcus Zervos; David McKinsey; Jeannette Lee; Timothy Babinchak; Robert W Bradsher; John D Cleary; David M Cohen; Larry Danziger; Mitchell Goldman; Jesse Goodman; Eileen Hilton; Newton E Hyslop; Daniel H Kett; Jon Lutz; Robert H Rubin; W Michael Scheld; Mindy Schuster; Bryan Simmons; David K Stein; Ronald G Washburn; Linda Mautner; Teng-Chiao Chu; Helene Panzer; Rebecca B Rosenstein; Jenia Booth Journal: Clin Infect Dis Date: 2003-05-08 Impact factor: 9.079
Authors: Anastasia Antoniadou; Harrys A Torres; Russell E Lewis; John Thornby; Gerald P Bodey; Jeffrey P Tarrand; Xiang-Yang Han; Kenneth V I Rolston; Amar Safdar; Issam I Raad; Dimitrios P Kontoyiannis Journal: Medicine (Baltimore) Date: 2003-09 Impact factor: 1.889
Authors: Cornelius J Clancy; Victor L Yu; Arthur J Morris; David R Snydman; M Hong Nguyen Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191
Authors: L Ostrosky-Zeichner; D Kontoyiannis; J Raffalli; K M Mullane; J Vazquez; E J Anaissie; J Lipton; P Jacobs; J H Jansen van Rensburg; J H Rex; W Lau; D Facklam; D N Buell Journal: Eur J Clin Microbiol Infect Dis Date: 2005-10 Impact factor: 3.267
Authors: Kelly C Wade; Daniel K Benjamin; David A Kaufman; Robert M Ward; Phillip B Smith; Bhuvana Jayaraman; Peter C Adamson; Marc R Gastonguay; Jeffrey S Barrett Journal: Pediatr Infect Dis J Date: 2009-08 Impact factor: 2.129
Authors: Lorenz Grigull; Andreas Beilken; Hansjoerg Schmid; P Kirschner; Karl-Walter Sykora; Christin Linderkamp; Frank Donnerstag; Lilia Goudeva; Hans-Gert Heuft; Karl Welte Journal: Support Care Cancer Date: 2006-02-16 Impact factor: 3.603